Stock Events

Stock Events

Bolt Biotherapeutics 

$6.43
0
+$0.07+1.1% Wednesday 04:00

Statistics

Day High
6.43
Day Low
6.43
52W High
-
52W Low
-
Volume
9
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 14
$0.09
Apr 14
$0.09
Jan 14
$0.09
Oct 13
$0.09
Apr 13
$0.07
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

1AprExpected
Q3 2025
Next
-6.11
-5.31
-4.52
-3.72
Expected EPS
-6.106667
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BOLT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, which is a platform that can be used for cancer immunotherapy, competing with Bolt's immune-stimulating antibody conjugates.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech, similar to Moderna, works on mRNA-based therapies and has a strong focus on personalized cancer vaccines, directly competing with Bolt's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a broad portfolio of oncology products, including cell therapies and antibody-drug conjugates, offering competitive alternatives to Bolt's therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a diverse oncology portfolio, including bispecific antibodies and CAR-T therapies, which could compete with Bolt's antibody-based therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops a range of biologic drugs, including those for cancer, with technologies that could rival Bolt's antibody conjugate platform.
Roche
RHHBY
Mkt Cap258.9B
Roche, through its Genentech arm, is a leader in oncology with a wide range of cancer treatments, including ADCs and immunotherapies, competing with Bolt's offerings.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a strong focus on oncology, with a portfolio that includes immunotherapies and targeted therapies, posing competition to Bolt's cancer treatment approaches.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad oncology portfolio, including immunotherapies and targeted treatments, which compete with Bolt's development of novel cancer therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis has a diverse oncology segment, including CAR-T cell therapy, radioligand therapy, and targeted therapies, offering competitive options to Bolt's technology.

About

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Show more...
CEO
Mr. William P. Quinn
Employees
52
Country
US
ISIN
US0977022039

Listings

F
DE
6LP0.F
XNAS
US
BOLT
BOATS
BOATS
BOLT.BOATS

0 Comments

Share your thoughts

FAQ

What is Bolt Biotherapeutics stock price today?▼
The current price of BOLT.BOATS is $6.43 USD — it has increased by +1.1% in the past 24 hours. Watch Bolt Biotherapeutics stock price performance more closely on the chart.
What is Bolt Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bolt Biotherapeutics stocks are traded under the ticker BOLT.BOATS.
When is the next Bolt Biotherapeutics earnings date?▼
Bolt Biotherapeutics is going to release the next earnings report on April 01, 2026.
What were Bolt Biotherapeutics earnings last quarter?▼
BOLT.BOATS earnings for the last quarter are -3.72 USD per share, whereas the estimation was -5.68 USD resulting in a +34.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
Does Bolt Biotherapeutics pay dividends?▼
Yes, BOLT.BOATS dividends are paid quarterly. The last dividend per share was 0.09 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Bolt Biotherapeutics have?▼
As of February 02, 2026, the company has 52 employees.
In which sector is Bolt Biotherapeutics located?▼
Bolt Biotherapeutics operates in the Health Care sector.
When did Bolt Biotherapeutics complete a stock split?▼
Bolt Biotherapeutics has not had any recent stock splits.
Where is Bolt Biotherapeutics headquartered?▼
Bolt Biotherapeutics is headquartered in Redwood City, US.